Genetic protection of hematopoietic stem cells for stable HIV control
造血干细胞的基因保护以稳定艾滋病毒控制
基本信息
- 批准号:8410026
- 负责人:
- 金额:$ 38.5万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-08-01 至 2017-07-31
- 项目状态:已结题
- 来源:
- 关键词:Adverse effectsAntiviral AgentsBindingBone MarrowBone Marrow TransplantationCCR5 geneCD34 geneCapsidCell TransplantsCell membraneCell surfaceCellsChemokine (C-C Motif) Receptor 5Chimeric ProteinsCytoprotectionDevelopmentDiseaseDisease remissionEngineeringEscape MutantFDA approvedGene ExpressionGenesGeneticGoalsGrowthHIVHIV Fusion InhibitorsHIV InfectionsHIV drug resistanceHIV therapyHIV-1HematopoieticHematopoietic stem cellsHumanHuman EngineeringImmuneIn VitroInfectionInterphase CellKnowledgeLeadLentivirus VectorLifeLife Cycle StagesLiverLong-Term EffectsLymphoidMediatingMembraneMembrane FusionMusOrganOrganoidsPatientsPharmaceutical PreparationsPositioning AttributePreventionProductionProteinsPublic HealthReagentResearchResistanceResistance developmentSafetySiteStagingStem cellsTestingTherapeuticTherapeutic StudiesThymus GlandTranscriptTransgenesTransplantationTropismUnited States National Institutes of HealthVariantViralViral Load resultbasecellular transductioncostcost effectivedesigngene therapyin vivoinhibitor/antagonistinnovationinterestmouse modelnovelpreventreconstitutionsmall hairpin RNAstemtherapeutic genevector
项目摘要
DESCRIPTION (provided by applicant): Hematopoietic stem/progenitor cell (HSPC) based gene therapy holds great promise to provide long-term control of HIV with a single treatment. Like HAART, it is essential to combine multiple drugs to effectively suppress HIV and prevent drug resistant HIV escape mutants. The overall hypothesis of this proposal is that stable introduction of highly potent combinations of anti-HIV genes capable of inhibiting multiple early and late steps of HIV viral lifecycle into HSPC will provide lifelong protection from HIV infection The safety and efficacy of anti-HIV HSPC gene therapy strategies, including inhibition of HIV, lowering of viral load and selective growth advantage of protected cells and prevention of resistance will be evaluated in the recently developed human bone marrow, liver and thymus (BLT) transplanted mouse model. Specific aims are 1) To develop novel multi-pronged anti-HIV gene therapeutic lentiviral vectors and characterize therapeutic reagents to inhibit HIV infection in HSPC and their progeny in vitro 2) To determine the long-term anti-gene expression and stable control of HIV through genetically engineered human HSPC transplant in the BLT mouse model. The approach is innovative because it focuses on novel HIV-1 target HSPC protection and the development of novel potent, broad-range early stage and late stage anti-HIV combinations, maximizing the potential to HIV replication not only in HSPC but also all potential target cells. The proposed research is significant because the results may ultimately lead to an innovative, more effective, more convenient, less toxic, safe and more cost effective way of controlling HIV infection than is currently available. The long-term goal is to advance HSPC based gene therapy research and make rapid progress towards providing a new therapy that leads to stable control of HIV by a single treatment.
PUBLIC HEALTH RELEVANCE: Our proposed research will positively impact public health with the development of an anti-HIV gene therapy by blocking the multiple early and late stages of the HIV infection. Ultimately, HIV infection will be controlled with a single treatment by protecting the hematopoietic stem cells and their progeny. This research will provide significant knowledge towards the long-term goal of the NIH "HIV cure."
描述(由申请人提供):基于造血干细胞/祖细胞(HSPC)的基因疗法有望通过一次治疗长期控制HIV。与HAART一样,必须联合使用多种药物才能有效抑制艾滋病毒并预防耐药艾滋病毒逃逸突变体。该建议的总体假设是,将能够抑制HIV病毒生命周期的多个早期和晚期步骤的高效抗HIV基因组合稳定地引入HSPC,将提供终生的HIV感染保护。将在新近建立的人骨髓、肝脏和胸腺(BLT)移植小鼠模型中评估其对降低病毒载量和保护细胞选择性生长优势以及预防耐药性的作用。具体目的是:1)开发新型多管齐下的抗HIV基因治疗慢病毒载体,并鉴定治疗试剂,在体外抑制HSPC及其后代的HIV感染;2)通过基因工程人HSPC移植BLT小鼠模型,确定HIV的长期抗基因表达和稳定控制。该方法是创新的,因为它专注于新的HIV-1靶点HSPC保护和开发新的有效的,广泛的早期和晚期抗HIV组合,最大限度地提高HIV在HSPC和所有潜在靶细胞中的复制潜力。这项拟议中的研究意义重大,因为其结果可能最终导致一种比目前可用的更创新、更有效、更方便、毒性更小、更安全、更经济有效的控制艾滋病毒感染的方法。长期目标是推进基于HSPC的基因治疗研究,并在提供一种通过单一治疗稳定控制HIV的新疗法方面取得快速进展。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Dong Sung An其他文献
Dong Sung An的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Dong Sung An', 18)}}的其他基金
Modulation of repopulation of anti HIV-1 gene-modified cells to enhance efficacy and safety
调节抗 HIV-1 基因修饰细胞的再增殖以提高功效和安全性
- 批准号:
10614651 - 财政年份:2020
- 资助金额:
$ 38.5万 - 项目类别:
Modulation of repopulation of anti HIV-1 gene-modified cells to enhance efficacy and safety
调节抗 HIV-1 基因修饰细胞的再增殖以提高功效和安全性
- 批准号:
10160822 - 财政年份:2020
- 资助金额:
$ 38.5万 - 项目类别:
Modulation of repopulation of anti HIV-1 gene-modified cells to enhance efficacy and safety
调节抗 HIV-1 基因修饰细胞的再增殖以提高功效和安全性
- 批准号:
10468655 - 财政年份:2020
- 资助金额:
$ 38.5万 - 项目类别:
Efficient Sendai virus mediated CRISPR/Cas9 gene editing to protect hematopoietic stem cells from HIV
高效仙台病毒介导的 CRISPR/Cas9 基因编辑保护造血干细胞免受 HIV 感染
- 批准号:
10402835 - 财政年份:2018
- 资助金额:
$ 38.5万 - 项目类别:
Efficient Sendai virus mediated CRISPR/Cas9 gene editing to protect hematopoietic stem cells from HIV
高效仙台病毒介导的 CRISPR/Cas9 基因编辑保护造血干细胞免受 HIV 感染
- 批准号:
10171759 - 财政年份:2018
- 资助金额:
$ 38.5万 - 项目类别:
Genetic protection of hematopoietic stem cells for stable HIV control
造血干细胞的基因保护以稳定艾滋病毒控制
- 批准号:
8881091 - 财政年份:2012
- 资助金额:
$ 38.5万 - 项目类别:
Genetic protection of hematopoietic stem cells for stable HIV control
造血干细胞的基因保护以稳定艾滋病毒控制
- 批准号:
8703001 - 财政年份:2012
- 资助金额:
$ 38.5万 - 项目类别:
Genetic protection of hematopoietic stem cells for stable HIV control
造血干细胞的基因保护以稳定艾滋病毒控制
- 批准号:
9101979 - 财政年份:2012
- 资助金额:
$ 38.5万 - 项目类别:
相似海外基金
Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
- 批准号:
23K18186 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别:
Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
- 批准号:
10560883 - 财政年份:2023
- 资助金额:
$ 38.5万 - 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10730692 - 财政年份:2021
- 资助金额:
$ 38.5万 - 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
- 批准号:
21K06459 - 财政年份:2021
- 资助金额:
$ 38.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
- 批准号:
10189880 - 财政年份:2021
- 资助金额:
$ 38.5万 - 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
- 批准号:
2404261 - 财政年份:2020
- 资助金额:
$ 38.5万 - 项目类别:
Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10222540 - 财政年份:2020
- 资助金额:
$ 38.5万 - 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10669717 - 财政年份:2020
- 资助金额:
$ 38.5万 - 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
- 批准号:
20K10713 - 财政年份:2020
- 资助金额:
$ 38.5万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
- 批准号:
10174522 - 财政年份:2020
- 资助金额:
$ 38.5万 - 项目类别: